England and Wales open for potential Leo Pharma recommendation

The National Institute for Health and Care Excellence (NICE) says it’s still possible for Leo Pharma to receive a recommendation for atopic eczema treatment Adtralza, and is currently reviewing comments from the firm.

Photo: Leo Pharma / PR

The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), is now clarifying an earlier statement, which suggested it did not recommend Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab).

”It has come to our attention that the note to media issues on 8 April 2022 in relation to this appraisal may have created the inaccurate impression that final guidance had been issues by NICE,” the authority writes in a statement, emphasizing that Leo Pharma has been able to comment on the indicative rejection until May 4.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs